These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15154280)

  • 21. The FDA, regulation, and the risk of stroke.
    Fleming GA
    N Engl J Med; 2000 Dec; 343(25):1886-7. PubMed ID: 11117982
    [No Abstract]   [Full Text] [Related]  

  • 22. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events.
    Maglione M; Miotto K; Iguchi M; Jungvig L; Morton SC; Shekelle PG
    Am J Psychiatry; 2005 Jan; 162(1):189-91. PubMed ID: 15625222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA issues alert on ephedra supplements in the USA.
    Nelson R
    Lancet; 2004 Jan; 363(9403):135. PubMed ID: 14733193
    [No Abstract]   [Full Text] [Related]  

  • 24. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid.
    Neff GW; Reddy KR; Durazo FA; Meyer D; Marrero R; Kaplowitz N
    J Hepatol; 2004 Dec; 41(6):1062-4. PubMed ID: 15582145
    [No Abstract]   [Full Text] [Related]  

  • 25. The anti-obesity effect of Ephedra sinica through modulation of gut microbiota in obese Korean women.
    Kim BS; Song MY; Kim H
    J Ethnopharmacol; 2014 Mar; 152(3):532-9. PubMed ID: 24556223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A critical evaluation of Internet marketing of products that contain ephedra.
    Ashar BH; Miller RG; Getz KJ; Pichard CP
    Mayo Clin Proc; 2003 Aug; 78(8):944-6. PubMed ID: 12911041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of herbal drugs in Mahuang decoction and their main components on intestinal transport characteristics of Ephedra alkaloids evaluated by a Caco-2 cell monolayer model.
    Zheng M; Zhou H; Wan H; Chen YL; He Y
    J Ethnopharmacol; 2015 Apr; 164():22-9. PubMed ID: 25660335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dietary supplement-related adverse events reported to the California Poison Control System.
    Dennehy CE; Tsourounis C; Horn AJ
    Am J Health Syst Pharm; 2005 Jul; 62(14):1476-82. PubMed ID: 15998927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Top-10 list of herbal and supplemental medicines used by cosmetic patients: what the plastic surgeon needs to know.
    Heller J; Gabbay JS; Ghadjar K; Jourabchi M; O'Hara C; Heller M; Bradley JP
    Plast Reconstr Surg; 2006 Feb; 117(2):436-45; discussion 446-7. PubMed ID: 16462323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No pain, no gain--exercise-induced rhabdomyolysis associated with the performance enhancer herbal supplement ephedra.
    Stahl CE; Borlongan CV; Szerlip M; Szerlip H
    Med Sci Monit; 2006 Sep; 12(9):CS81-4. PubMed ID: 16940935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ergogenic aids: an update on ephedra.
    Keisler BD; Hosey RG
    Curr Sports Med Rep; 2005 Aug; 4(4):231-5. PubMed ID: 16004835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse events of herbal food supplements for body weight reduction: systematic review.
    Pittler MH; Schmidt K; Ernst E
    Obes Rev; 2005 May; 6(2):93-111. PubMed ID: 15836459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relative safety of ephedra compared with other herbal products.
    Bent S; Tiedt TN; Odden MC; Shlipak MG
    Ann Intern Med; 2003 Mar; 138(6):468-71. PubMed ID: 12639079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Food and Drug Administration's actions on ephedra and androstenedione: understanding their potential impacts on the protections of the Dietary Supplement Health and Education Act.
    Siegner AW
    Food Drug Law J; 2004; 59(4):617-28. PubMed ID: 15880877
    [No Abstract]   [Full Text] [Related]  

  • 35. [Necessity of applying pharmacovigilance in post-marketing safety monitoring of traditional Chinese medicine injections].
    Wang HN; Chen W; Fu Z; Du WM; He J
    Zhongguo Zhong Yao Za Zhi; 2008 Mar; 33(5):612-4. PubMed ID: 18536393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine.
    Samenuk D; Link MS; Homoud MK; Contreras R; Theoharides TC; Wang PJ; Estes NA
    Mayo Clin Proc; 2002 Jan; 77(1):12-6. PubMed ID: 11795249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Health risks raised by ephedra in food supplements].
    van Riel AJ; de Vries I; Meulenbelt J
    Ned Tijdschr Geneeskd; 2003 Oct; 147(41):2017-9. PubMed ID: 14587144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA to ban sales of dietary supplements containing ephedra.
    Ling AM
    J Law Med Ethics; 2004; 32(1):184-6. PubMed ID: 15152444
    [No Abstract]   [Full Text] [Related]  

  • 39. Dietary supplements containing ephedra alkaloids.
    Hutchins GM
    N Engl J Med; 2001 Apr; 344(14):1095-6; author reply 1096-7. PubMed ID: 11291668
    [No Abstract]   [Full Text] [Related]  

  • 40. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (Ma-huang) as determined by high performance liquid chromatography.
    Gurley BJ; Wang P; Gardner SF
    J Pharm Sci; 1998 Dec; 87(12):1547-53. PubMed ID: 10189265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.